Synergistic Inhibitions of Gram-Negative Bacteria by Combination Treatment with Ciprofloxacin and a Novel Glucolipid.

Psychrophilic fungus Pseudogymnoascus sp. OUCMDZ-4032 derived from Antarctica was cultivated under 16 °C to produce a new glucolipid compound (1). Its structure was elucidated by analysis of detailed spectroscopic data, acid hydrolysis and 1-phenyl-3-methyl-5-pyrazolone precolumn derivatization, and...

Full description

Bibliographic Details
Published in:Chemistry & Biodiversity
Main Authors: Yang, Liyuan, Zhang, Qingqing, Yu, Deng, Zhu, Weiming, Wang, Yi
Format: Article in Journal/Newspaper
Language:English
Published: Wiley 2024
Subjects:
Antibiotics
Biological activity
Glycolipids
Natural products
Synergistic inhibition
Antarc*
Antarctica
Online Access:https://doi.org/10.1002/cbdv.202400578
https://pubmed.ncbi.nlm.nih.gov/38634186
Description
Summary:Psychrophilic fungus Pseudogymnoascus sp. OUCMDZ-4032 derived from Antarctica was cultivated under 16 °C to produce a new glucolipid compound (1). Its structure was elucidated by analysis of detailed spectroscopic data, acid hydrolysis and 1-phenyl-3-methyl-5-pyrazolone precolumn derivatization, and 13C NMR quantum chemical calculations. Though compound 1 did not show inhibitory activity against bacteria, it can reduce the minimum inhibitory concentration (MIC) of ciprofloxacin against Gram-negative bacteria Pseudomonas aeruginosa, Escherichia coli, and Salmonella paratyphi by 1024, 256 and 256-fold. Compound 1 showed potential as a synergistically inhibiting adjuvant in co-administration with antibiotic to enhance antibacterial activities.

Similar Items